DYN Dyne Therapeutics Inc.

Biotech Analyst Ratings

Latest News

1. 16 May 2022 Dyne Therapeutics Presents New In Vivo Data from DYNE-101 at ASGCT Annual Meeting Demonstrating Low Monthly Dosing Leads to Robust DMPK RNA Knockdown

   - Initiation of Dosing in Multiple Ascending Dose Clinical Trial for DYNE-101 in Patients with Myotonic Dystrophy Type 1 Anticipated in Mid-2022 -
   

   WALTHAM, Mass., May 16, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, is presenting new in vivo data from DYNE-101, its myotonic dystrophy type 1 (DM1) candidate, at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting today demonstrating robust knockdown of DMPK RNA in multiple muscles with low monthly dosing.

   "We are excited to present these new data that show monthly dosing of DYNE-101 led to a substantial knockdown of…

   View Full Article
2. 02 May 2022 Dyne Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

   - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Anticipated in Mid-2022 -
   

   WALTHAM, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2022 and business highlights.

   "We are fully focused on advancing multiple programs to the clinic. We are executing on our plans to submit in the second quarter our response to the FDA relating to our IND for DYNE-251 in DMD as well as regulatory filings in multiple countries for DYNE-101 in DM1 with the goal to initiate…

   View Full Article
3. 17 March 2022 selfologi Chooses Digital Technology Consulting Partner Grid Dynamics to Launch Its Cosmetic Treatment Platform

   SAN RAMON, CA / ACCESSWIRE / March 17, 2022 / Grid Dynamics Holdings, Inc. (NASDAQ:DYN) (Grid Dynamics), a leader in enterprise-level digital engineering services and solutions, today announced it has launched a fully transactional B2B and B2C commerce application for selfologi, a Dubai-based digital platform aiming to become the number one cosmetic treatment destination in the Middle East.

   Key Takeaways:

   • In partnership with Grid Dynamics, commercetools, and other partners, Dubai-based digital platform selfologi launches a fully transactional B2B and B2C content and commerce marketplace
   • selfologi's cosmetic treatment site was built on an accelerated timeline with a composable commerce architecture, leveraging best-of-breed advanced technologies…

   View Full Article
4. 10 March 2022 Dyne Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights

   - Response to FDA for DYNE-251 IND in DMD on Track for Submission in the Second Quarter of 2022 -
   
   - Initiation of Patient Dosing in Multiple Ascending Dose Clinical Trials for DYNE-251 in DMD and DYNE-101 in DM1 Planned in Mid-2022 -

   WALTHAM, Mass., March 10, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the fourth quarter and full year 2021 and recent business highlights.

   "In 2021 we made significant achievements throughout the business. We generated platform-validating preclinical data across our programs, including demonstrating sustained knockdown…

   View Full Article
5. 03 March 2022 Dyne Therapeutics Appoints Carlo Incerti, M.D., to its Board of Directors

   WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors. Dr. Incerti has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development.
   

   "We are excited to have Carlo joining the Board as we advance Dyne's programs into the clinic. He brings an extensive track record in global drug development, including from his time at Sanofi Genzyme where he played a leading role in pioneering therapies for rare and genetic diseases," said Jason Rhodes…

   View Full Article